TLDR Block hit $200 billion in total loans across Cash App Borrow, Afterpay, and Square Loans since launch Proprietary underwriting delivers 38% more approvals TLDR Block hit $200 billion in total loans across Cash App Borrow, Afterpay, and Square Loans since launch Proprietary underwriting delivers 38% more approvals

Block (XYZ) Stock: Company Crosses $200 Billion in Total Lending Volume

2026/01/21 21:24
3 min read

TLDR

  • Block hit $200 billion in total loans across Cash App Borrow, Afterpay, and Square Loans since launch
  • Proprietary underwriting delivers 38% more approvals than traditional methods at identical loss rates
  • Cash App Borrow posts 97% repayment rate, Afterpay 96% on-time payments, Square Loans under 3% losses
  • Square Financial Services originated $20 billion and now handles all Cash App Borrow loans
  • Stock fell 5% Tuesday to $62.63, recovered 0.3% Wednesday morning to $62.82

Block revealed Tuesday it has issued more than $200 billion in loans through its three lending platforms. The total spans Cash App Borrow, Afterpay, and Square Loans since the company started lending in 2013.


XYZ Stock Card
Block, Inc., XYZ

Shares dropped 5% to $62.63 Tuesday as broader markets tumbled. The S&P 500 fell 2.06% after President Trump threatened new tariffs on Europe.

Block recovered slightly Wednesday, climbing 0.3% to $62.82 in premarket action. The company carries a $40 billion market cap.

Real-Time Data Powers Approval Gains

Block’s underwriting system uses behavioral data collected in real time rather than traditional credit reports. The company says this approach generates 38% more Cash App Borrow approvals while maintaining identical loss rates to conventional methods.

Cash App Borrow focuses on short-term consumer loans averaging 21 days. Block reports 97% of borrowers repay on schedule.

Afterpay’s buy now, pay later model records 96% of payments arriving on time. Square Loans, designed for small businesses, keeps loss rates under 3%.

Risk lead Brian Boates said the company uses scale for inclusion instead of selectivity. Block estimates nearly 100 million Americans lack access to affordable credit under traditional scoring systems.

Square Financial Services operates as Block’s in-house bank. It has originated over $20 billion across Square Loans and Cash App Borrow. The bank began handling all Cash App Borrow originations in 2025.

Earnings and Analyst Updates

Truist analyst Matthew Coad lifted Block’s price target to $72 from $68. The Hold rating stays in place. Coad expects solid Q4 results but warned tougher comparisons could limit upside surprises.

Block recently tested showing select customers their “Cash App Score.” This internal metric determines Cash App Borrow eligibility. The company claims its models beat traditional credit scores across multiple loan categories.

Financial metrics show Block maintains a 2.18 current ratio and 8.24% return on assets.

Competitive Landscape Heats Up

Block faces rivals across all three lending products. Cash App competes with PayPal in consumer fintech. Afterpay battles Affirm and other BNPL providers. Square fights established payment processors for merchant share.

Higher lending volumes bring risk if the economy weakens. Rising delinquencies or reduced small-business activity could pressure the stable loss rates Block touts.

Block reports Q4 earnings February 19. Investors will focus on Cash App Borrow trends, Afterpay repayment data, and Square payment volumes.

The post Block (XYZ) Stock: Company Crosses $200 Billion in Total Lending Volume appeared first on Blockonomi.

Market Opportunity
Blockstreet Logo
Blockstreet Price(BLOCK)
$0.007636
$0.007636$0.007636
+0.43%
USD
Blockstreet (BLOCK) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26